NO20015546L - Behandling av refrakt¶re humane tumorer med epidermale vekstfaktorreseptorantagonister - Google Patents
Behandling av refrakt¶re humane tumorer med epidermale vekstfaktorreseptorantagonisterInfo
- Publication number
- NO20015546L NO20015546L NO20015546A NO20015546A NO20015546L NO 20015546 L NO20015546 L NO 20015546L NO 20015546 A NO20015546 A NO 20015546A NO 20015546 A NO20015546 A NO 20015546A NO 20015546 L NO20015546 L NO 20015546L
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- growth factor
- receptor antagonists
- factor receptor
- epidermal growth
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31228499A | 1999-05-14 | 1999-05-14 | |
US37402899A | 1999-08-13 | 1999-08-13 | |
PCT/US2000/011756 WO2000069459A1 (en) | 1999-05-14 | 2000-05-01 | Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20015546D0 NO20015546D0 (no) | 2001-11-13 |
NO20015546L true NO20015546L (no) | 2002-01-14 |
Family
ID=26978320
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20015546A NO20015546L (no) | 1999-05-14 | 2001-11-13 | Behandling av refrakt¶re humane tumorer med epidermale vekstfaktorreseptorantagonister |
Country Status (20)
Country | Link |
---|---|
US (3) | US20020012663A1 (sk) |
EP (2) | EP2042194A3 (sk) |
JP (2) | JP2003520195A (sk) |
KR (1) | KR20020000223A (sk) |
CN (1) | CN1200734C (sk) |
AU (1) | AU782994C (sk) |
BG (1) | BG106110A (sk) |
BR (1) | BR0010524A (sk) |
CA (1) | CA2373815A1 (sk) |
CZ (1) | CZ20014083A3 (sk) |
EE (1) | EE200100603A (sk) |
HK (1) | HK1047236A1 (sk) |
HU (1) | HUP0201480A3 (sk) |
IL (1) | IL146480A0 (sk) |
MX (1) | MXPA01011632A (sk) |
NO (1) | NO20015546L (sk) |
PL (1) | PL365999A1 (sk) |
RU (1) | RU2294761C2 (sk) |
SK (1) | SK16522001A3 (sk) |
WO (1) | WO2000069459A1 (sk) |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7060808B1 (en) * | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
US20030224001A1 (en) * | 1998-03-19 | 2003-12-04 | Goldstein Neil I. | Antibody and antibody fragments for inhibiting the growth of tumors |
ZA200007412B (en) * | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
US20040127470A1 (en) * | 1998-12-23 | 2004-07-01 | Pharmacia Corporation | Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist |
JP2002534468A (ja) | 1999-01-13 | 2002-10-15 | バイエル コーポレイション | p38キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素 |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
IL146480A0 (en) * | 1999-05-14 | 2002-07-25 | Imclone Systems Inc | Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
US7740841B1 (en) * | 2000-01-28 | 2010-06-22 | Sunnybrook Health Science Center | Therapeutic method for reducing angiogenesis |
JP2004527456A (ja) * | 2000-08-09 | 2004-09-09 | イムクローン システムズ インコーポレイティド | Egf受容体拮抗剤による過増殖性の疾患の治療 |
US20020151508A1 (en) * | 2001-02-09 | 2002-10-17 | Schering Corporation | Methods for treating proliferative diseases |
EP1236474A1 (en) * | 2001-02-26 | 2002-09-04 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Negative regulation of epidermal growth factor receptor activity by Mig-6 |
US20080008704A1 (en) * | 2001-03-16 | 2008-01-10 | Mark Rubin | Methods of treating colorectal cancer with anti-epidermal growth factor antibodies |
US7498029B2 (en) | 2001-05-01 | 2009-03-03 | The General Hospital Corporation | Photoimmunotherapies for cancer using combination therapies |
SK14632003A3 (sk) * | 2001-05-08 | 2004-03-02 | Merck Patent Gmbh | Kombinovaná terapia pri použití anti-EGFR protilátok a antihormonálnych činidiel |
US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
WO2002092771A2 (en) | 2001-05-11 | 2002-11-21 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
KR100719624B1 (ko) * | 2001-05-18 | 2007-05-21 | 석정철 | 시각장애인을 위한 접착형 점자유도블록 및점자유도블록의 접착방법 |
US20050271663A1 (en) * | 2001-06-28 | 2005-12-08 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
EP1399484B1 (en) * | 2001-06-28 | 2010-08-11 | Domantis Limited | Dual-specific ligand and its use |
WO2004003019A2 (en) * | 2002-06-28 | 2004-01-08 | Domantis Limited | Immunoglobin single variant antigen-binding domains and dual-specific constructs |
EP2324825A1 (en) | 2002-02-11 | 2011-05-25 | Bayer Healthcare LLC | Aryl ureas with angiogenesis inhibiting activity |
ATE494000T1 (de) * | 2002-03-08 | 2011-01-15 | Max Planck Gesellschaft | Verwendung von egfr transaktivierungsinhibitoren für menschlichen krebs |
US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
US20040147428A1 (en) * | 2002-11-15 | 2004-07-29 | Pluenneke John D. | Methods of treatment using an inhibitor of epidermal growth factor receptor |
TWI229650B (en) * | 2002-11-19 | 2005-03-21 | Sharp Kk | Substrate accommodating tray |
JP2006523090A (ja) * | 2002-12-27 | 2006-10-12 | ドマンティス リミテッド | リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体 |
JPWO2004060400A1 (ja) * | 2003-01-06 | 2006-05-11 | 那波 宏之 | 上皮成長因子受容体を分子標的とする抗精神病薬 |
EP1599484A2 (en) * | 2003-02-21 | 2005-11-30 | Chugai Seiyaku Kabushiki Kaisha | Process for the preparation of hexacyclic camptothecin derivatives |
US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
ATE366108T1 (de) | 2003-05-20 | 2007-07-15 | Bayer Pharmaceuticals Corp | Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten |
CN101966338A (zh) | 2003-06-09 | 2011-02-09 | 塞缪尔·瓦克萨尔 | 用胞外拮抗物和胞内拮抗物抑制受体酪氨酸激酶的方法 |
EP1493445A1 (en) * | 2003-07-04 | 2005-01-05 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibition of stress-induced ligand-dependent EGFR activation |
NZ580384A (en) | 2003-07-23 | 2011-03-31 | Bayer Pharmaceuticals Corp | 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions |
WO2005027970A1 (ja) * | 2003-09-24 | 2005-03-31 | Kyowa Hakko Kogyo Co., Ltd. | 癌治療用医薬 |
CN1898240B (zh) * | 2003-10-15 | 2011-08-03 | Osi制药公司 | 咪唑并吡嗪类酪氨酸激酶抑制剂 |
JP4734319B2 (ja) * | 2004-03-19 | 2011-07-27 | イムクローン・リミテッド・ライアビリティ・カンパニー | ヒト抗上皮成長因子受容体抗体 |
BRPI0509576A (pt) * | 2004-04-02 | 2007-05-29 | Osi Pharm Inc | composto, método de tratamento de um paciente tendo uma condição que é mediada pela atividade de proteìna quinase, e, composição farmacêutica |
CA2563502A1 (en) | 2004-04-09 | 2005-10-20 | Chugai Seiyaku Kabushiki Kaisha | Novel water-soluble prodrug |
CN1968706A (zh) * | 2004-06-03 | 2007-05-23 | 霍夫曼-拉罗奇有限公司 | 用顺铂和egfr-抑制剂治疗 |
CA2566971A1 (en) * | 2004-06-03 | 2005-12-15 | F. Hoffmann-La Roche Ag | Treatment with irinotecan (cpt-11) and an egfr-inhibitor |
CN1960732A (zh) * | 2004-06-03 | 2007-05-09 | 霍夫曼-拉罗奇有限公司 | 用吉西他滨和egfr-抑制剂治疗 |
BRPI0511780A (pt) * | 2004-06-03 | 2008-01-15 | Hoffmann La Roche | tratamento com oxoliplatina e um inibidor de egrf |
US20060084666A1 (en) * | 2004-10-18 | 2006-04-20 | Harari Paul M | Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor |
US20060084691A1 (en) * | 2004-10-18 | 2006-04-20 | Bilal Piperdi | Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor |
US20060084675A1 (en) * | 2004-10-18 | 2006-04-20 | Thomas Efferth | Combined treatment with artesunate and an epidermal growth factor receptor kinase inhibitor |
US20070099856A1 (en) * | 2005-05-13 | 2007-05-03 | Gumerlock Paul H | Combined treatment with docetaxel and an epidermal growth factor receptor kinase inhibitor using an intermittent dosing regimen |
TW200744603A (en) | 2005-08-22 | 2007-12-16 | Chugai Pharmaceutical Co Ltd | Novel anticancer concomitant drug |
AU2006305169A1 (en) * | 2005-10-19 | 2007-04-26 | Chugai Seiyaku Kabushiki Kaisha | Preventive or therapeutic agents for pancreatic cancer, ovarian cancer, or liver cancer comprising a novel water-soluble prodrug |
WO2007049361A1 (ja) * | 2005-10-27 | 2007-05-03 | Stelic Corp. | 肝線維化抑制剤 |
EP1957536A2 (en) * | 2005-12-01 | 2008-08-20 | Domantis Limited | Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1 |
US8575164B2 (en) * | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
EP2094268A2 (en) * | 2006-05-26 | 2009-09-02 | Bayer HealthCare, LLC | Drug combinations with substituted diaryl ureas for the treatment of cancer |
KR100723641B1 (ko) * | 2006-06-07 | 2007-06-04 | 실버레이 주식회사 | 다중 조리가 가능한 솥 |
US20070286864A1 (en) * | 2006-06-09 | 2007-12-13 | Buck Elizabeth A | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors |
WO2008046107A2 (en) * | 2006-10-13 | 2008-04-17 | The Regents Of The University Of California | Novel inhibitors of the egfr kinase targeting the asymmetric activating dimer interface |
MX2009007987A (es) * | 2007-01-25 | 2010-03-01 | Dana Farber Cancer Inst Inc | Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante. |
US9023356B2 (en) * | 2007-03-15 | 2015-05-05 | Ludwig Institute For Cancer Research Ltd | Treatment method using EGFR antibodies and SRC inhibitors and related formulations |
MX2009012968A (es) * | 2007-06-06 | 2010-04-01 | Domantis Ltd | Polipeptidos, dominios variables de anticuerpo y antagonistas. |
JP5532486B2 (ja) | 2007-08-14 | 2014-06-25 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | Egf受容体を標的とするモノクローナル抗体175ならびにその誘導体および用途 |
US20100323957A1 (en) * | 2007-11-19 | 2010-12-23 | The Regents Of The University Of California The Office Of The President | Novel assay for inhibitors of egfr |
WO2009091939A1 (en) * | 2008-01-18 | 2009-07-23 | Osi Pharmaceuticals, Inc. | Imidazopyrazinol derivatives for the treatment of cancers |
ES2471452T3 (es) * | 2008-03-05 | 2014-06-26 | Novartis Ag | Uso de 5-(2,6-di-morfolin-4-il-pirimidin-4-il)-4-trifluorometil-piridin-2-ilamina para el tratamiento de carcinoma de pulmón de células no pequeñas con resistencia adquirida a los moduladores del receptor del factor de crecimiento epid�rmico (EGFR). |
JP2011520970A (ja) * | 2008-05-19 | 2011-07-21 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | 置換されたイミダゾピラジン類およびイミダゾトリアジン類 |
EP2408479A1 (en) | 2009-03-18 | 2012-01-25 | OSI Pharmaceuticals, LLC | Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor |
ES2572728T3 (es) | 2009-03-20 | 2016-06-02 | F. Hoffmann-La Roche Ag | Anticuerpos anti-HER biespecíficos |
CA2752826A1 (en) | 2009-04-20 | 2010-10-28 | OSI Pharmaceuticals, LLC | Preparation of c-pyrazine-methylamines |
JP2012526138A (ja) * | 2009-05-07 | 2012-10-25 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 副腎皮質癌を治療するためのosi−906の使用 |
US20110076232A1 (en) * | 2009-09-29 | 2011-03-31 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
BR122014024883A2 (pt) | 2010-05-14 | 2019-08-20 | Dana-Farber Cancer Institute, Inc. | Compostos no tratamento de neoplasia |
MX354217B (es) | 2010-05-14 | 2018-02-19 | Dana Farber Cancer Inst Inc | Composiciones y metodos para el tratamiento de leucemia. |
RU2457546C1 (ru) * | 2011-03-09 | 2012-07-27 | Учреждение Российской академии медицинских наук Научный центр реконструктивной и восстановительной хирургии Сибирского отделения РАМН (НЦРВХ СО РАМН) | Способ моделирования аденокарциномы толстой кишки человека |
WO2012129145A1 (en) | 2011-03-18 | 2012-09-27 | OSI Pharmaceuticals, LLC | Nscle combination therapy |
CN103826661B (zh) | 2011-04-21 | 2019-03-05 | 西雅图基因公司 | 新的结合剂-药物缀合物(adc)及其用途 |
CA2845179A1 (en) | 2011-08-31 | 2013-03-07 | Genentech, Inc. | Diagnostic markers |
AU2012321248A1 (en) | 2011-09-30 | 2014-04-24 | Genentech, Inc. | Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to EGFR kinase inhibitor in tumours or tumour cells |
RU2016122654A (ru) | 2013-11-08 | 2017-12-14 | Дана-Фарбер Кэнсер Инститьют, Инк. | Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка |
CN106456653A (zh) | 2014-02-28 | 2017-02-22 | 腾沙治疗公司 | 高胰岛素血症相关病症的治疗 |
RU2016141385A (ru) | 2014-03-24 | 2018-04-28 | Дженентек, Инк. | Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf |
WO2017205465A2 (en) | 2016-05-24 | 2017-11-30 | Griswold Karl Edwin | Antibodies and methods of making same |
JP7197865B2 (ja) * | 2017-07-18 | 2022-12-28 | 協和キリン株式会社 | 抗ヒトccr1モノクローナル抗体 |
IL277748B1 (en) * | 2018-04-06 | 2024-03-01 | Seagen Inc | Camptothecin peptide conjugates |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU22545A1 (es) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
FR2388385B1 (fr) * | 1977-04-18 | 1982-01-08 | Hitachi Metals Ltd | Piece d'ornement fixee par des aimants permanents |
US4510924A (en) * | 1980-07-10 | 1985-04-16 | Yale-New Haven Hospital, Inc. | Brachytherapy devices and methods employing americium-241 |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
US5866363A (en) * | 1985-08-28 | 1999-02-02 | Pieczenik; George | Method and means for sorting and identifying biological information |
US4816401A (en) * | 1985-09-09 | 1989-03-28 | University Of Rochester | Serum free cell culture medium |
CA1275922C (en) * | 1985-11-28 | 1990-11-06 | Harunobu Amagase | Treatment of cancer |
US4846782A (en) | 1986-03-14 | 1989-07-11 | Schering Corporation | Treatment of cancer with interferon and radiotherapy |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US4763642A (en) * | 1986-04-07 | 1988-08-16 | Horowitz Bruce S | Intracavitational brachytherapy |
US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5260203A (en) * | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
JP3040121B2 (ja) * | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
US5470571A (en) * | 1988-01-27 | 1995-11-28 | The Wistar Institute | Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425 |
IL89489A0 (en) | 1988-03-09 | 1989-09-10 | Hybritech Inc | Chimeric antibodies directed against human carcinoembryonic antigen |
WO1989009622A1 (en) | 1988-04-15 | 1989-10-19 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
WO1989009825A1 (en) | 1988-04-16 | 1989-10-19 | Celltech Limited | Method for producing recombinant dna proteins |
AU4128089A (en) * | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
GB8823869D0 (en) * | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
WO1991000916A2 (en) * | 1989-07-06 | 1991-01-24 | The Regents Of The University Of California | Receptors for fibroblast growth factors |
US5705157A (en) * | 1989-07-27 | 1998-01-06 | The Trustees Of The University Of Pennsylvania | Methods of treating cancerous cells with anti-receptor antibodies |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5196446A (en) | 1990-04-16 | 1993-03-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Certain indole compounds which inhibit EGF receptor tyrosine kinase |
GB9015198D0 (en) * | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
AU662311B2 (en) | 1991-02-05 | 1995-08-31 | Novartis Ag | Recombinant antibodies specific for a growth factor receptor |
CZ282603B6 (cs) * | 1991-03-06 | 1997-08-13 | Merck Patent Gesellschaft Mit Beschränkter Haftun G | Humanizované a chimerické monoklonální protilátky |
US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
JP4124480B2 (ja) * | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
US5565332A (en) * | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5559235A (en) | 1991-10-29 | 1996-09-24 | Glaxo Wellcome Inc. | Water soluble camptothecin derivatives |
ES2227512T3 (es) * | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
WO1993021319A1 (en) | 1992-04-08 | 1993-10-28 | Cetus Oncology Corporation | HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES |
US6177401B1 (en) * | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
CA2150262C (en) * | 1992-12-04 | 2008-07-08 | Kaspar-Philipp Holliger | Multivalent and multispecific binding proteins, their manufacture and use |
US5855885A (en) * | 1993-01-22 | 1999-01-05 | Smith; Rodger | Isolation and production of catalytic antibodies using phage technology |
US5550114A (en) * | 1993-04-02 | 1996-08-27 | Thomas Jefferson University | Epidermal growth factor inhibitor |
US5679683A (en) | 1994-01-25 | 1997-10-21 | Warner-Lambert Company | Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
US5861499A (en) * | 1994-02-10 | 1999-01-19 | Imclone Systems Incorporated | Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain |
US5840301A (en) * | 1994-02-10 | 1998-11-24 | Imclone Systems Incorporated | Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors |
US6448077B1 (en) * | 1994-02-10 | 2002-09-10 | Imclone Systems, Inc. | Chimeric and humanized monoclonal antibodies specific to VEGF receptors |
AU686843B2 (en) * | 1994-02-23 | 1998-02-12 | Pfizer Inc. | 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents |
WO1995024190A2 (en) * | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
US5844093A (en) * | 1994-03-17 | 1998-12-01 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Anti-EGFR single-chain Fvs and anti-EGFR antibodies |
US5656655A (en) | 1994-03-17 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Styryl-substituted heteroaryl compounds which inhibit EGF receptor tyrosine kinase |
US5869465A (en) * | 1994-04-08 | 1999-02-09 | Receptagen Corporation | Methods of receptor modulation and uses therefor |
US5468754A (en) | 1994-04-19 | 1995-11-21 | Bionumerik Pharmaceuticals, Inc. | 11,7 substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof |
US5604233A (en) | 1994-04-28 | 1997-02-18 | Bionumerik Pharmaceuticals, Inc. | Lactone stable formulation of 7-ethyl camptothecin and methods for uses thereof |
US5626862A (en) * | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5663144A (en) * | 1995-05-03 | 1997-09-02 | The Trustees Of The University Of Pennsylvania | Compounds that bind to p185 and methods of using the same |
US5726181A (en) | 1995-06-05 | 1998-03-10 | Bionumerik Pharmaceuticals, Inc. | Formulations and compositions of poorly water soluble camptothecin derivatives |
US7060808B1 (en) * | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
WO1996040210A1 (en) * | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
ES2177925T3 (es) * | 1996-01-23 | 2002-12-16 | Novartis Ag | Pirrolopirimidinas y procedimientos para su preparacion. |
GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
GB9707800D0 (en) * | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
US5925566A (en) * | 1996-06-06 | 1999-07-20 | University Of Massachusetts | Non-activated receptor complex proteins and uses thereof |
US6004967A (en) * | 1996-09-13 | 1999-12-21 | Sugen, Inc. | Psoriasis treatment with quinazoline compounds |
US5942602A (en) * | 1997-02-13 | 1999-08-24 | Schering Aktiengessellschaft | Growth factor receptor antibodies |
US20030105057A1 (en) * | 1997-03-19 | 2003-06-05 | Yale University | Methods and compositions for stimulating apoptosis and cell death or for inhibiting cell growth and cell attachment |
US5914269A (en) * | 1997-04-04 | 1999-06-22 | Isis Pharmaceuticals, Inc. | Oligonucleotide inhibition of epidermal growth factor receptor expression |
US20020173629A1 (en) * | 1997-05-05 | 2002-11-21 | Aya Jakobovits | Human monoclonal antibodies to epidermal growth factor receptor |
US6235883B1 (en) * | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
US6417168B1 (en) * | 1998-03-04 | 2002-07-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods of treating tumors |
ZA200007412B (en) * | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
US7396810B1 (en) * | 2000-08-14 | 2008-07-08 | Oregon Health Sciences University | Compositions and methods for treating cancer by modulating HER-2 and EGF receptors |
IL146480A0 (en) * | 1999-05-14 | 2002-07-25 | Imclone Systems Inc | Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
DE60042693D1 (de) * | 1999-08-27 | 2009-09-17 | Genentech Inc | Dosierung für die behandlung mit anti erbb2-antikörpern |
US6699473B2 (en) * | 2000-10-13 | 2004-03-02 | Uab Research Foundation | Human anti-epidermal growth factor receptor single-chain antibodies |
AU2002239486A1 (en) * | 2000-12-08 | 2002-06-18 | Uab Research Foundation | Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody |
US20040116330A1 (en) * | 2001-04-27 | 2004-06-17 | Kenichiro Naito | Preventive/therapeutic method for cancer |
US7595378B2 (en) * | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
CN100497389C (zh) * | 2001-06-13 | 2009-06-10 | 根马布股份公司 | 表皮生长因子受体(egfr)的人单克隆抗体 |
DE10163459A1 (de) * | 2001-12-21 | 2003-07-03 | Merck Patent Gmbh | Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor |
ATE494000T1 (de) * | 2002-03-08 | 2011-01-15 | Max Planck Gesellschaft | Verwendung von egfr transaktivierungsinhibitoren für menschlichen krebs |
DE60326226D1 (de) * | 2002-03-21 | 2009-04-02 | Cayman Chemical Co | Prostaglandin f2 alpha analoga in kombination mit einem antimikrobiellen mittel zur behandlung von glaukom |
JPWO2003101491A1 (ja) * | 2002-06-03 | 2005-09-29 | 三菱ウェルファーマ株式会社 | Her2又は/及びEGFR発現又は活性化対象に用いる予防又は/及び治療剤 |
BR0315123A (pt) * | 2002-10-10 | 2005-08-16 | Merck Patent Gmbh | Composições farmacêuticas direcionadas a receptores erb-b1 |
EP1493445A1 (en) * | 2003-07-04 | 2005-01-05 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibition of stress-induced ligand-dependent EGFR activation |
DK1687338T3 (da) * | 2003-11-07 | 2011-02-07 | Ablynx Nv | Camelidae enkeltdomæne-antistoffer VHH, der er rettet mod epidermal vækstfaktor-receptor og anvendelser deraf |
DE10355904A1 (de) * | 2003-11-29 | 2005-06-30 | Merck Patent Gmbh | Feste Formen von anti-EGFR-Antikörpern |
JP2007522157A (ja) * | 2004-02-12 | 2007-08-09 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 抗egfr抗体の高濃縮液体製剤 |
TW200533339A (en) * | 2004-03-16 | 2005-10-16 | Bristol Myers Squibb Co | Therapeutic synergy of anti-cancer compounds |
JP4734319B2 (ja) * | 2004-03-19 | 2011-07-27 | イムクローン・リミテッド・ライアビリティ・カンパニー | ヒト抗上皮成長因子受容体抗体 |
PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
-
2000
- 2000-05-01 IL IL14648000A patent/IL146480A0/xx unknown
- 2000-05-01 EP EP08015392A patent/EP2042194A3/en not_active Withdrawn
- 2000-05-01 PL PL00365999A patent/PL365999A1/xx not_active IP Right Cessation
- 2000-05-01 EE EEP200100603A patent/EE200100603A/xx unknown
- 2000-05-01 HU HU0201480A patent/HUP0201480A3/hu unknown
- 2000-05-01 CZ CZ20014083A patent/CZ20014083A3/cs unknown
- 2000-05-01 AU AU46871/00A patent/AU782994C/en not_active Ceased
- 2000-05-01 CA CA002373815A patent/CA2373815A1/en not_active Abandoned
- 2000-05-01 EP EP00928671A patent/EP1218032A4/en not_active Withdrawn
- 2000-05-01 JP JP2000617919A patent/JP2003520195A/ja active Pending
- 2000-05-01 KR KR1020017014494A patent/KR20020000223A/ko not_active Application Discontinuation
- 2000-05-01 BR BR0010524-4A patent/BR0010524A/pt not_active IP Right Cessation
- 2000-05-01 WO PCT/US2000/011756 patent/WO2000069459A1/en active IP Right Grant
- 2000-05-01 MX MXPA01011632A patent/MXPA01011632A/es not_active Application Discontinuation
- 2000-05-01 RU RU2001130771/14A patent/RU2294761C2/ru active
- 2000-05-01 CN CNB008103216A patent/CN1200734C/zh not_active Expired - Fee Related
- 2000-05-01 SK SK1652-2001A patent/SK16522001A3/sk unknown
-
2001
- 2001-04-24 US US09/840,146 patent/US20020012663A1/en not_active Abandoned
- 2001-11-13 NO NO20015546A patent/NO20015546L/no not_active Application Discontinuation
- 2001-11-14 BG BG106110A patent/BG106110A/bg unknown
- 2001-11-30 US US09/996,954 patent/US20030157104A1/en not_active Abandoned
-
2002
- 2002-12-03 HK HK02108768.1A patent/HK1047236A1/zh unknown
-
2004
- 2004-12-20 US US11/018,950 patent/US20050112120A1/en not_active Abandoned
-
2008
- 2008-09-24 JP JP2008244928A patent/JP2009120583A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2373815A1 (en) | 2000-11-23 |
JP2009120583A (ja) | 2009-06-04 |
KR20020000223A (ko) | 2002-01-05 |
CN1200734C (zh) | 2005-05-11 |
JP2003520195A (ja) | 2003-07-02 |
AU4687100A (en) | 2000-12-05 |
NO20015546D0 (no) | 2001-11-13 |
WO2000069459A1 (en) | 2000-11-23 |
EP1218032A4 (en) | 2005-05-25 |
PL365999A1 (en) | 2005-01-24 |
EP2042194A3 (en) | 2009-04-22 |
HUP0201480A3 (en) | 2009-03-30 |
BG106110A (bg) | 2002-04-30 |
CZ20014083A3 (cs) | 2002-08-14 |
HUP0201480A2 (en) | 2002-08-28 |
EE200100603A (et) | 2003-02-17 |
CN1361700A (zh) | 2002-07-31 |
SK16522001A3 (sk) | 2002-10-08 |
US20020012663A1 (en) | 2002-01-31 |
HK1047236A1 (zh) | 2003-02-14 |
AU782994C (en) | 2006-08-24 |
MXPA01011632A (es) | 2002-11-07 |
EP2042194A2 (en) | 2009-04-01 |
RU2294761C2 (ru) | 2007-03-10 |
EP1218032A1 (en) | 2002-07-03 |
US20030157104A1 (en) | 2003-08-21 |
IL146480A0 (en) | 2002-07-25 |
BR0010524A (pt) | 2002-05-28 |
AU782994B2 (en) | 2005-09-15 |
US20050112120A1 (en) | 2005-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20015546D0 (no) | Behandling av refrakt¶re humane tumorer med epidermale vekstfaktorreseptorantagonister | |
NO20030603D0 (no) | Behandling av hyperprolifererende sykdommer med epidermale, vekstfaktorreseptorantagonister | |
EE05481B1 (et) | Kinasoliini derivaadid kasvajate raviks | |
ATE399541T1 (de) | Epidermale wachstumsfaktor rezeptor antagonisten zur behandlung stark vermehrter schleimsekretion in der lunge | |
EE200200118A (et) | Terapeutilised kinasoliini derivaadid, nende valmistamise meetod ning kasutamine | |
PL348634A1 (en) | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases | |
NO20014769L (no) | Preparat for behandling og diagnostikk av brystcancer og fremgangsmater for anvendelse derav | |
DE60033030D1 (de) | Verwendung von gegen cd20 gerichteten antikörpern zur behandlung der graft versus host krankheit | |
DE60019556D1 (de) | 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit | |
DE59900101D1 (de) | Medizinisches Instrument zum Präparieren von Gewebe | |
EP1317226A4 (en) | TREATMENT OF HUMAN HERPESVIRUS BY HYPERTHERMIA | |
DE60042252D1 (de) | Implantierbare medizinische Vorrichtung | |
DE60019555D1 (de) | 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit | |
ATE231869T1 (de) | Pyridopyranoazepinderivate, ihre herstellung und therapeutische verwendung | |
DE60030164D1 (de) | 3-heteroarylidenyl-2-indolinon derivate mit protein kinase modulierender activity und zur verwendung in der krebschemotherapie | |
NO20012367D0 (no) | Behandling av tumorer ved administrering av veksthormonfrigjörende forbindelser og deres antagonister | |
ATE265862T1 (de) | Programmierte ovarielle stimulationsbehandlungprotokoll unter verwendung von oralen kontrazeptiva | |
DE50114605D1 (de) | No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz | |
ATE234617T1 (de) | Verwendung des saredutant und seiner pharmazeutisch akzeptablen salze zur behandlung von schwere depression | |
HK1046915A1 (zh) | 人類肝細胞生長因子受體酪氨酸激酶催化結構域及鑒定其抑制劑的方法 | |
DE60018200D1 (de) | Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen | |
DE60002043D1 (de) | 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b]indol-1-carboxamid-derivate, ihre herstellung und therapeutische verwendung | |
DE60112423D1 (de) | Verwendung von substituierten distamycin-acryloylderivaten zur behandlung von tumoren die mit erhöhten glutathion-spiegeln zusammenhängen | |
DE50011084D1 (de) | Verwendung von azolen zur prävention von strahlen-induziertem hautkrebs | |
ZA200109347B (en) | Treatment of refractory human tumors with epidermal growth factor receptor antagonists. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |